Literature DB >> 24383131

Alleviating the pain of unresectable hepatic tumors by percutaneous cryoablation: experience in 73 patients.

Long Xin'an, Zeng Jianying, Niu Lizhi, Yao Fei, Wang Xiaohua, Chen Jibing, Li Jialiang, Xu Kecheng.   

Abstract

Pain caused by liver tumors can be alleviated by cryoablation, but little is known about the analgesic effects and duration of pain alleviation. We retrospectively reviewed the changes in the severity of pain before and after percutaneous cryoablation of hepatic tumors. Each patient enrolled in this study had a single hepatic tumor; patients with large tumors (major diameter, P5 cm) underwent transarterial chemoembolization (TACE) first and then cryoablation. Severe abdominal pain that was not controlled with long-lasting oral analgesics was treated with opioid injections. In all 73 study patients, severe abdominal pain was gradually eased 5 days after cryosurgery, completely disappeared after 15 days and did not recur for more than 8 weeks. There were no differences in analgesic effects between patients with hepatocellular carcinomas and those with liver metastasis (P > 0.05). The patients were divided into four groups depending on their pain outcomes: (i) immediate relief (n = 6), severe abdominalgia was no longer present after cryosurgery; (ii) delayed relief (n = 11), severe abdominalgia disappeared gradually within 15 days after the cryosurgery; (iii) always pain-free (n = 39), severe abdominalgia was not present before or after treatment; and (iv) new pain (n = 17), abdominalgia developed after treatment and disappeared within 15 days. In summary, percutaneous cryoablation of hepatic tumors caused short-term pain in some patients, but this pain disappeared within 15 days. Moreover, the pain-relieving effect of this treatment was sustained for at least 8 weeks, without severe side effects.

Entities:  

Mesh:

Year:  2013        PMID: 24383131

Source DB:  PubMed          Journal:  Cryobiology        ISSN: 0011-2240            Impact factor:   2.487


  8 in total

1.  Percutaneous Image-Guided Cryoablation of Hepatic Tumors: Single-Center Experience With Intermediate to Long-Term Outcomes.

Authors:  Daniel I Glazer; Servet Tatli; Paul B Shyn; Mark G Vangel; Kemal Tuncali; Stuart G Silverman
Journal:  AJR Am J Roentgenol       Date:  2017-09-27       Impact factor: 3.959

2.  Percutaneous cryoablation in early stage hepatocellular carcinoma: analysis of local tumor progression factors.

Authors:  Dong Kyu Kim; Kichang Han; Jong Yun Won; Gyoung Min Kim; Joon Ho Kwon; Man Deuk Kim
Journal:  Diagn Interv Radiol       Date:  2020-03       Impact factor: 2.630

Review 3.  Percutaneous Cryoablation for Liver Cancer.

Authors:  Li-Zhi Niu; Jia-Liang Li; Ke-Cheng Xu
Journal:  J Clin Transl Hepatol       Date:  2014-09-15

4.  Clinical Practice Guidelines for Cryosurgery of Pancreatic Cancer: A Consensus Statement From the China Cooperative Group of Cryosurgery on Pancreatic Cancer, International Society of Cryosurgery, and Asian Society of Cryosurgery.

Authors:  Lihua He; Lizhi Niu; Nikolai N Korpan; Sajio Sumida; Yueyong Xiao; Jiaping Li; Barlian Sutedja; Youyong Lu; Jiansheng Zuo; Jianguo Liu; Kecheng Xu
Journal:  Pancreas       Date:  2017-09       Impact factor: 3.327

5.  Observation of the effect of targeted therapy of 64-slice spiral CT combined with cryoablation for liver cancer.

Authors:  Qiao-Huan Yan; Dian-Guo Xu; Yan-Feng Shen; Ding-Ling Yuan; Jun-Hui Bao; Hai-Bin Li; Ying-Gang Lv
Journal:  World J Gastroenterol       Date:  2017-06-14       Impact factor: 5.742

Review 6.  Recent progress in cryoablation cancer therapy and nanoparticles mediated cryoablation.

Authors:  Kijung Kwak; Bo Yu; Robert J Lewandowski; Dong-Hyun Kim
Journal:  Theranostics       Date:  2022-02-14       Impact factor: 11.556

7.  Percutaneous computed tomography-guided cryoablation for recurrent retroperitoneal soft tissue sarcoma: a study of safety and efficacy.

Authors:  Wenzhe Fan; Lizhi Niu; Yu Wang; Yingqiang Zhang; Xuehua Yao; Guosheng Tan; Jianyong Yang; Jiaping Li
Journal:  Oncotarget       Date:  2016-07-05

8.  Cryoablation combined with transarterial infusion of pembrolizumab (CATAP) for liver metastases of melanoma: an ambispective, proof-of-concept cohort study.

Authors:  Lujun Shen; Han Qi; Shuanggang Chen; Fei Cao; Lin Xie; Ying Wu; Weimei Ma; Ze Song; Hui Yuan; Tao Zhang; Dandan Li; Xizhi Wen; Qifeng Chen; Wang Li; Xiaoshi Zhang; Weijun Fan
Journal:  Cancer Immunol Immunother       Date:  2020-04-24       Impact factor: 6.968

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.